Indian Companies Should Follow Teva Path, With Market-specific Plans, Global Scale – Experts
This article was originally published in PharmAsia News
Rapid global expansion with control on costs may keep Indian drug companies in business. The larger the size the better, say experts from IMS Health and Accenture.
You may also be interested in...
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.